Developing new drugs is not for the faint-hearted. “It’s a pretty perilous journey,” says Paul Nioi, vice-president of discovery and translational research at Alnylam Pharmaceuticals. “It’s expensive ...
When the IBM PC was new, I served as the president of the San Francisco PC User Group for three years. That’s how I met PCMag’s editorial team, who brought me on board in 1986. In the years since that ...